Clinical Trials

Multiple Myeloma

NCT06152575 2026-04-16

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Phase 1 Not yet recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07532525 2026-04-16

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

12 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

67 enrolled

Multiple Myeloma

NCT07523737 2026-04-15

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Multiple Myeloma, Recurrence

NCT04108195 2026-04-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

290 enrolled

Multiple Myeloma

NCT04181827 2026-04-13

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT04667663 2026-04-13

CPD-DARA

16 enrolled

Multiple Myeloma

NCT04722146 2026-04-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT05050097 2026-04-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Multiple Myeloma

NCT05438043 2026-04-13

A Study of Daratumumab

500 enrolled

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT06768489 2026-04-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

140 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma

NCT06948084 2026-04-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

80 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07463807 2026-04-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

162 enrolled

Multiple Myeloma

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Completed

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04234022 2026-04-09

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

Recruiting

70 enrolled

Multiple Myeloma

NCT04902443 2026-04-08

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Phase 1 Recruiting

58 enrolled

Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT02659930 2026-04-01

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

62 enrolled

Sarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT04162210 2026-03-31

DREAMM-3

325 enrolled 10 charts

Phase 2 Active not recruiting

Multiple Myeloma

NCT04835129 2026-03-27

IMPEDE

28 enrolled

Multiple Myeloma

NCT05020236 2026-03-27

MAGNETISMM-5

944 enrolled

Multiple Myeloma

NCT06413498 2026-03-27

iMMagine-3

450 enrolled

Multiple Myeloma

NCT07452198 2026-03-25

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

358 enrolled

Multiple Myeloma

NCT05519085 2026-03-24

SUCCESSOR-1

810 enrolled

Multiple Myeloma, Recurrence

NCT04910568 2026-03-19

CAMMA 1

126 enrolled